China Issues New Rules on Fentanyl-Related Criminal Cases

The notable element is the explicit split between medicinal and non-medicinal uses, which signals a regulatory approach that targets illicit channels while leaving legitimate pharmaceutical handling intact. For compliance teams at firms handling pharmaceutical precursors or cross-border health trade, this is the category of guidance that reshapes risk assessment. Whether other jurisdictions adopt a similar medicinal-versus-illicit distinction is the open question worth tracking.